PDS Biotechnology Corp. (PDSB)

Over the past six months, PDS Biotech's stock was impacted by several key events. In January 2026, the FDA aligned on using Progression Free Survival (PFS) as a primary endpoint for the Phase 3 VERSATILE-003 clinical trial. In December 2025, the Japan Patent Office issued a new composition of matter patent for PDS0101. In November 2025, PDS Biotech reported its Third Quarter 2025 financial results, showing a net loss of $9.0 million and a decrease in cash balance, and announced an up to $11.1 million Registered Direct Offering. Translational data demonstrating strong immunological and clinical activity of PDS0101 and PDS01ADC were presented at SITC 2025, and the Versatile 002 trial showed a median overall survival of 39.3 months in patients with HPV-16 positive head and neck cancer. As of January 9, 2026, the share price was $1.07, representing a decline of 24.65% over the past year and a decline of 21.30% over the past six months.

As a clinical-stage biopharmaceutical company, PDS Biotechnology Corp. currently has no commercially approved products, therefore, there is no direct product demand seasonality to report. The company's focus is on research, development, and clinical trials, which are not typically subject to seasonal demand fluctuations.

PDS Biotechnology Corporation is a clinical-stage immunotherapy company focused on developing novel immunotherapies for cancer and infectious diseases, operating within the Healthcare sector, specifically in the Pharmaceuticals & Biotech industry. Its core technological platforms are Versamune® and Infectimune™, and its pipeline includes PDS0101 (Versamune® HPV) in late-stage clinical trials for HPV16-positive cancers, PDS01ADC, an investigational IL-12 fused antibody drug conjugate, and other investigational immunotherapies like PDS0102, PDS0103, PDS0104, PDS0202, PDS-0201 and PDS0203.

PDS Biotechnology Corporation is headquartered in Princeton, New Jersey, United States, with its drug discovery and development activities primarily conducted in the United States. The company has an international intellectual property presence, demonstrated by securing a new composition of matter patent for PDS0101 in Japan in December 2025.

PDS Biotechnology's brand reputation has been positively influenced by its clinical progress and regulatory interactions. Promising clinical data from the VERSATILE-002 Phase 2 trial and positive presentations of clinical data at major conferences have contributed to a favorable scientific reputation. Constructive dialogue with the FDA and the securing of a new patent in Japan for PDS0101 also enhances its intellectual property standing.

PDS Biotechnology Corporation's ownership is a mix of institutional, retail, and individual investors. Institutional ownership has been around 12.3% to 15.89% of the company's stock. Insiders own approximately 1.54% to 3.03%, while public companies and individual investors hold a significant portion, estimated at around 90.48%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Geode Capital Management, LLC, Citadel Advisors Llc, Inspirion Wealth Advisors LLC, Squarepoint Ops LLC, Renaissance Technologies Llc, Blair William & Co/il, Caption Management, LLC and Armistice Capital, LLC.